BIOTECHNOLOGY VALUE FUND II LP
CIK 1102444 · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KYMR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
40TH FL
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 1,671,048 | $114.84 | $191.90M | -$1.43B | 4 | 2026-06-26 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 62,383 | $15.70 | $979.4K | $0 | 1 | 2025-06-17 | |
| MLTX | Director | 10,235,089 | $11.81 | $120.88M | $0 | 1 | 2025-06-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,792,157 | $2.65 | $10.05M | $28.21M | 1 | 2023-11-03 | |
| RAIN | 1,479,460 | $0.53 | $784.1K | $21.20M | 3 | 2021-09-23 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 4,336,875 | $38.00 | $164.80M | $33.14M | 2 | 2020-10-08 | |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 1,948,819 | $40.17 | $78.28M | $21.66M | 6 | 2020-09-01 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 3,927 | $13.60 | $53.4K | -$1.57M | 1 | 2019-09-10 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,372,596 | $0.04 | $284.9K | $20.07M | 2 | 2018-11-21 |
| SNDX | 85,038 | $13.22 | $1.12M | $0 | 1 | 2018-06-20 | |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 1,898,293 | — | — | $3.08M | 4 | 2015-02-09 | |
| CCXI | 485,412 | $10.25 | $4.98M | $11.62M | 1 | 2013-09-13 | |
| NBIX | 756,600 | $145.87 | $110.37M | $2.48M | 1 | 2011-10-12 | |
| CAPS | 32 | $2.61 | $84 | $1.55M | 2 | 2011-08-22 | |
| Celera CORP (CRA) Delisted | 31,520,834 | — | — | $155.25M | 4 | 2011-05-10 | |
| AVIGEN INC \DE (AVGN) Delisted | 15,674,378 | — | — | -$5.6K | 1 | 2009-11-20 | |
| RPRX | 2,145,776 | $64.76 | $138.96M | -$3.60M | 1 | 2009-09-24 | |
| CRIS | 4,097 | $0.38 | $1.5K | -$17.08M | 1 | 2009-04-29 | |
| LGND | 10%+ Owner | 2,663,034 | $308.30 | $821.01M | $5.66M | 5 | 2009-01-27 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 8,135,099 | — | — | $773.0K | 1 | 2008-11-12 |
Recent Filings · Page 4 of 5
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-08-22 | CAPS | Buy (P) | +473,400 | $123.1K | EDGAR |
| 2011-08-01 | CAPS | Buy (P) | +5,725,500 | $1.43M | EDGAR |
| 2011-05-10 | Celera CORP (CRA) Delisted | Buy (P) | +11,026,400 | $88.73M | EDGAR |
| 2011-04-22 | Celera CORP (CRA) Delisted | Buy (P) | +5,889,600 | $47.12M | EDGAR |
| 2011-04-19 | Celera CORP (CRA) Delisted | Buy (P) | +1,117,200 | $9.02M | EDGAR |
| 2011-04-14 | Celera CORP (CRA) Delisted | Buy (P) | +1,290,000 | $10.39M | EDGAR |
| 2009-11-20 | AVIGEN INC \DE (AVGN) Delisted | Sell (S) | −3,756 | -$5.6K | EDGAR |
| 2009-09-24 | RPRX | Sell (S) | −2,124,000 | -$3.60M | EDGAR |
| 2009-07-13 | — | Buy (P) | +154,200 | $471.5K | |
| 2009-04-29 | CRIS | Sell (S) | −14,850,000 | -$17.08M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.